Loss of heterozygosity in the HLA locus, leading to a restricted MHC allele diversity in the tumour, are a prevalent tumour escape mechanism and is associated with poor outcomes in checkpoint blockade therapy [62, 63]. This evidence concerns the gene HLA-C and neoplasm.